Ocrevus
Genentech shares results from phase 3 trial for MS treatment
July 13, 2023Research and Development Genentech, MS, Neurology, Ocrevus, clinical trial
Genentech has announced positive results from its phase 3 OCARINA II trial which assessed Ocrevus (ocrelizumab) as a twice-a-year, ten-minute …
Multi-study data confirms Ocrevus’ long-term efficacy in reducing disability progression in multiple sclerosis
September 13, 2019Medical Communications, Research and Development ECTRIMS, Ocrevus, Roche, multiple sclerosis, pharma
Roche has taken the opportunity at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) conference in Stockholm …
Ocrevus becomes first NICE-approved therapy on the NHS for primary progressive multiple sclerosis
May 9, 2019Sales and Marketing Genentech, NHS, NICE, Ocrevus, UK
NICE has announced its final appraisal decision on Genentech’s Ocrevus (ocrelizumab), choosing to recommend the drug for use on the …
Roche’s Ocrevus shows earlier, better outcomes in primary progressive and relapsing MS
October 11, 2018Research and Development Ocrevus, Roche, multiple sclerosis, pharma
Roche has unveiled new five-year data from three Phase 3 open-label extension studies investigating the efficacy of Ocrevus (ocrelizumab) in …
NICE rejects Roche’s Ocrevus in primary progressive multiple sclerosis
September 10, 2018Sales and Marketing NICE, Ocrevus, Roche, UK, multiple sclerosis, pharma
Of the 100,000 MS patients in England, around one in eight have the primary progressive form (PPMS), which brings debilitating …
NICE turns down Roche’s Ocrevus in early primary progressive multiple sclerosis
June 29, 2018Medical Communications, Sales and Marketing NICE, Ocrevus, Roche, pharma
Roche’s sometimes strained relationship with NICE continues as the health watchdog for England and Wales chose to reject the former’s …
Roche’s Ocrevus extends time-to-wheelchair by 7 years in progressive MS patients
June 14, 2018Research and Development Ocrevus, Roche, multiple sclerosis, pharma
Roche has lifted the curtain on more promising data at Phase 3 for its humanised anti-CD20 monoclonal antibody Ocrevus (ocrelizumab), …
Roche suffers Ocrevus knockback by NICE
April 6, 2018Medical Communications, Sales and Marketing Ocrevus, Roche, biotech, drugs, multiple sclerosis, pharma, pharmaceutical
Roche’s multiple sclerosis drug, Ocrevus (ocrelizumab), has been a big new growth driver for the company, especially in the US, …
Roche’s Ocrevus gets the go ahead in Europe for two forms of MS
January 12, 2018Medical Communications, Sales and Marketing Europe, European Commission, Ocrevus, Roche, multiple sclerosis, pharma
Roche has revealed that its multiple sclerosis (MS) drug Ocrevus (ocrelizumab) has been awarded marketing approval in Europe by the …
EMA recommends approval of Roche’s Ocrevus in relapsing forms of multiple sclerosis
November 13, 2017Sales and Marketing MS, Ocrevus, Roche, multiple sclerosis, pharma
Roche has revealed that its humanised monoclonal antibody Ocrevus (ocrelizumab) received a positive recommendation from the Committee for Medical Products …
Roche chalks up Swiss approval for multiple sclerosis drug Ocrevus
September 28, 2017Sales and Marketing Ocrevus, Roche, multiple sclerosis, pharma, pharmaceutical
Roche has announced that its drug Ocrevus (ocrelizumab) has received marketing approval in Switzerland for the treatment of active relapsing …
Roche’s Ocrevus more effective than Merck’s Rebif, company claims
September 14, 2016Research and Development Merck, Ocrevus, Rebif, Roche, multiple sclerosis
Roche has announced new results from the Phase III studies of investigational medicine Ocrevus (ocrelizumab) studying relapsing multiple sclerosis (RMS) …
Roche says EMA accepts its marketing applications for Ocrevus to treat multiple sclerosis
June 28, 2016Manufacturing and Production, Research and Development, Sales and Marketing EMA, Ocrevus, Roche, US FDA, drug development, drug trial, multiple sclerosis, priority review, regulation
Cancer drugmaker Roche (SIX: ROG) said the European Medicines Agency (EMA) has accepted the marketing authorisation application (MAA) for its …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
